BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12962879)

  • 1. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders.
    Peraira JR; Segovia J; Fuertes B; Fernández JA; Escudier JM; Salas C; Pulpón LA
    Transplant Proc; 2003 Aug; 35(5):2009-10. PubMed ID: 12962879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
    Keay S; Oldach D; Wiland A; Klassen D; Schweitzer E; Abruzzo LV; Kumar D; Bartlett S
    Clin Infect Dis; 1998 Mar; 26(3):596-600. PubMed ID: 9524829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load.
    Brouwer RM; Balk AH; Weimar W
    Transpl Int; 1992; 5 Suppl 1():S259-61. PubMed ID: 14621795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
    Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
    Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
    Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.